

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

Dated: 5/20/04

Signature:

Valerie J. Sarosky
(Valerie J. Sarosky)

Docket No.: CDSI-P01-040
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ashton et al.

Application No.: 10/762421

Confirmation No.: 4529

Filed: January 22, 2004

Art Unit: 1615

For: SUSTAINED RELEASE DEVICE AND
METHOD FOR OCULAR DELIVERY OF
CARBONIC ANHYDRASE INHIBITORS

Examiner: Not Yet Assigned

REQUEST FOR CORRECTED FILING RECEIPT

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has the following errors:

Domestic Priority data as claimed by applicant

In line 2, please change the word "CIP" to **CON** (emphasis added) so that it reads "which is a **CON** of 09/558,207 04/26/2000 PAT 6,375,972."

In the last line, please change the application number "60/501,974" to **60/501,975** (emphasis added).

Enclosed are copies of the Filing Receipt with changes noted in red, along with a copy of the previously filed first page of the specification and Declaration for Patent Application submitted herewith.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction. It is understood that the Patent Office will issue a corrected Filing Receipt in this and, if applicable, any other affected applications.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. CDSI-P01-040 from which the undersigned is authorized to draw.

Dated: May 20, 2004

Respectfully submitted,

By 

David P. Halstead

Registration No.: 44,735
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/762,421	01/22/2004	1615	1340	CDSI-P01-040	5	21	5

28120
 ROPES & GRAY LLP
 ONE INTERNATIONAL PLACE
 BOSTON, MA 02110-2624

Ropes & Gray
 Intellectual Property Dept.

APR 28 2004

CONFIRMATION NO. 4529

FILING RECEIPT



OC000000012452941

Date Mailed: 04/26/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Paul Ashton, Boston, MA;
 Hong Guo, Belmont, MA;

Assignment For Published Patent Application

Control Delivery Systems, Inc., Watertown, MA;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/096,877 03/14/2002
 which is a CIP of 09/558,207 04/26/2000 PAT 6,375,972

This application 10/762,421
 is a CIP of 10/428,214 05/02/2003
 which claims benefit of 60/377,974 05/07/2002
 and claims benefit of 60/437,576 12/31/2002
 and claims benefit of 60/452,348 03/06/2003
 This application 10/762,421
 claims benefit of 60/442,499 01/24/2003
 and claims benefit of 60/483,316 06/26/2003
 and claims benefit of 60/482,677 06/26/2003
 and claims benefit of 60/501,974 09/11/2003

Foreign Applications

60/501,975

If Required, Foreign Filing License Granted: 04/26/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Ropes & Gray

Symbol # CDSI-P01-040

Action Due: Review Filing Receipt/Assignment

Deadline(s): 26 Jun 2004 / 26 Jul 2004

Non-Publication Request: No

Early Publication Request: No

Title

Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Sustained Release Device and Method for Ocular Delivery of Carbonic Anhydrase Inhibitors

RELATED APPLICATIONS

This application is a continuation-in-part of co-pending U.S. application 10/096,877, filed March 14, 2002, which is a continuation of U.S. application 09/558,207, now U.S. Patent 6,375,972, filed April 26, 2000, the disclosures of which are incorporated herein by reference.

This application is also a continuation-in-part of co-pending U.S. application 10/428,214, filed May 2, 2003, which claims benefit of provisional U.S. applications 60/377,974, filed May 7, 2002, 60/437,576, filed December 31, 2002, and 60/452,348, filed March 6, 2003, the disclosures of each of which are incorporated by reference herein.

This application claims priority of co-pending provisional U.S. applications 60/442,499, filed January 24, 2003; 60/483,316, filed June 26, 2003; 60/482,677, filed on June 26, 2003; and 60/501,975 filed September 11, 2003, the disclosures of each of which are incorporated by reference herein.

FIELD OF THE INVENTION

The present invention relates to the field of sustained drug delivery to the eye, and particularly to the treatment and/or prevention of raised intraocular pressure, such as that associated with glaucoma or the use of corticosteroids, by sustained delivery of carbonic anhydrase inhibitors to the eye.

BACKGROUND OF THE INVENTION

1. Carbonic Anhydrase Inhibitors.

Glaucoma is one of the leading causes of blindness in the developed countries of the world. The chief pathophysiological feature of glaucoma is raised intraocular pressure. Surgery and/or drugs intended to lower intraocular pressure are the most common treatments for glaucoma. The principal pharmaceutical treatments in use today are the administration of miotics (e.g., pilocarpine, carbachol and echothiophate), which open the trabecular meshwork to increase the rate of fluid flow out of the eye; and the administration of beta blockers (e.g., timolol, levobunolol,